ZA200604046B - A2B Adenosine receptor antagonists - Google Patents
A2B Adenosine receptor antagonists Download PDFInfo
- Publication number
- ZA200604046B ZA200604046B ZA200604046A ZA200604046A ZA200604046B ZA 200604046 B ZA200604046 B ZA 200604046B ZA 200604046 A ZA200604046 A ZA 200604046A ZA 200604046 A ZA200604046 A ZA 200604046A ZA 200604046 B ZA200604046 B ZA 200604046B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- ethyl
- contacting
- propyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/719,102 US7125993B2 (en) | 2001-11-09 | 2003-11-21 | A2B adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604046B true ZA200604046B (en) | 2007-11-28 |
Family
ID=34633233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604046A ZA200604046B (en) | 2003-11-21 | 2006-05-19 | A2B Adenosine receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7125993B2 (https=) |
| EP (1) | EP1685132B1 (https=) |
| JP (1) | JP4769728B2 (https=) |
| KR (1) | KR101140186B1 (https=) |
| CN (1) | CN100415748C (https=) |
| AU (1) | AU2004292529B2 (https=) |
| CA (1) | CA2546733C (https=) |
| ES (1) | ES2391178T3 (https=) |
| IL (1) | IL175759A0 (https=) |
| MX (1) | MXPA06005637A (https=) |
| NZ (1) | NZ547357A (https=) |
| RU (1) | RU2374247C2 (https=) |
| TW (1) | TWI365879B (https=) |
| WO (1) | WO2005051951A1 (https=) |
| ZA (1) | ZA200604046B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| MXPA03008967A (es) * | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| JP2005538190A (ja) * | 2002-07-29 | 2005-12-15 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋潅流イメージング |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| EP1799221A1 (en) * | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| CN101076343A (zh) | 2004-10-20 | 2007-11-21 | Cv医药有限公司 | A2a腺苷受体激动剂的应用 |
| EP1891070A1 (en) * | 2005-06-16 | 2008-02-27 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| WO2007092372A1 (en) | 2006-02-03 | 2007-08-16 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| AU2007227021B2 (en) | 2006-03-17 | 2012-12-20 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| WO2008028140A1 (en) * | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
| US20080170990A1 (en) * | 2006-09-29 | 2008-07-17 | Cv Therapeutics, Inc. | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease |
| ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
| WO2008086096A2 (en) * | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
| JP2011528364A (ja) * | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アテローム性動脈硬化症の治療 |
| MX2011003168A (es) * | 2008-09-29 | 2011-05-19 | Gilead Sciences Inc | Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples. |
| BR112012032766A2 (pt) | 2010-06-30 | 2019-09-24 | Gilead Sciences Inc | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
| ES2975753T3 (es) | 2018-03-05 | 2024-07-12 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| CN116322698A (zh) * | 2020-09-04 | 2023-06-23 | 泰昂治疗公司 | 腺苷a2b受体拮抗剂的共晶 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452788A (en) | 1982-04-21 | 1984-06-05 | Warner-Lambert Company | Substituted 8-phenylxanthines |
| US4539707A (en) * | 1982-06-01 | 1985-09-03 | Aerotron, Inc. | Compressed single side band communications system and method |
| US4593095A (en) | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| US4558051A (en) | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| DE8817122U1 (de) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| IT1229195B (it) | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
| DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| TW252044B (https=) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
| US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| ES2189079T3 (es) | 1998-04-24 | 2003-07-01 | Leuven K U Res & Dev | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
| US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| CA2333947C (en) | 1998-06-01 | 2010-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
-
2003
- 2003-11-21 US US10/719,102 patent/US7125993B2/en not_active Expired - Lifetime
-
2004
- 2004-11-15 CN CNB2004800342770A patent/CN100415748C/zh not_active Expired - Fee Related
- 2004-11-15 ES ES04811022T patent/ES2391178T3/es not_active Expired - Lifetime
- 2004-11-15 RU RU2006117349/04A patent/RU2374247C2/ru not_active IP Right Cessation
- 2004-11-15 NZ NZ547357A patent/NZ547357A/xx not_active IP Right Cessation
- 2004-11-15 WO PCT/US2004/038136 patent/WO2005051951A1/en not_active Ceased
- 2004-11-15 CA CA2546733A patent/CA2546733C/en not_active Expired - Fee Related
- 2004-11-15 KR KR1020067009840A patent/KR101140186B1/ko not_active Expired - Fee Related
- 2004-11-15 EP EP04811022A patent/EP1685132B1/en not_active Expired - Lifetime
- 2004-11-15 MX MXPA06005637A patent/MXPA06005637A/es active IP Right Grant
- 2004-11-15 JP JP2006541295A patent/JP4769728B2/ja not_active Expired - Fee Related
- 2004-11-15 AU AU2004292529A patent/AU2004292529B2/en not_active Ceased
- 2004-11-19 TW TW093135764A patent/TWI365879B/zh not_active IP Right Cessation
-
2006
- 2006-05-18 IL IL175759A patent/IL175759A0/en active IP Right Grant
- 2006-05-19 ZA ZA200604046A patent/ZA200604046B/en unknown
- 2006-08-22 US US11/508,592 patent/US7521554B2/en not_active Expired - Fee Related
-
2009
- 2009-01-28 US US12/361,409 patent/US20090137802A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060281921A1 (en) | 2006-12-14 |
| JP4769728B2 (ja) | 2011-09-07 |
| HK1093736A1 (en) | 2007-03-09 |
| JP2007512335A (ja) | 2007-05-17 |
| US20090137802A1 (en) | 2009-05-28 |
| US7521554B2 (en) | 2009-04-21 |
| TWI365879B (en) | 2012-06-11 |
| NZ547357A (en) | 2009-08-28 |
| CA2546733A1 (en) | 2005-06-09 |
| KR101140186B1 (ko) | 2012-05-23 |
| AU2004292529B2 (en) | 2011-04-14 |
| RU2374247C2 (ru) | 2009-11-27 |
| AU2004292529A1 (en) | 2005-06-09 |
| WO2005051951A1 (en) | 2005-06-09 |
| CN100415748C (zh) | 2008-09-03 |
| EP1685132A1 (en) | 2006-08-02 |
| US7125993B2 (en) | 2006-10-24 |
| IL175759A0 (en) | 2006-09-05 |
| ES2391178T3 (es) | 2012-11-22 |
| CN1882588A (zh) | 2006-12-20 |
| TW200530237A (en) | 2005-09-16 |
| EP1685132B1 (en) | 2012-08-29 |
| KR20060100434A (ko) | 2006-09-20 |
| RU2006117349A (ru) | 2007-11-27 |
| US20040176399A1 (en) | 2004-09-09 |
| CA2546733C (en) | 2015-03-17 |
| MXPA06005637A (es) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200604046B (en) | A2B Adenosine receptor antagonists | |
| CA2874461C (en) | Formulations containing reversible covalent compounds | |
| AU2017201134C1 (en) | Purinone derivative hydrochloride | |
| EP3026045B1 (en) | Quinoline derivative | |
| DE60112268T2 (de) | Verwendung von quinazolinderivate als inhibitoren der angiogenese | |
| EP3193880B1 (en) | Inhibiting the transient receptor potential a1 ion channel | |
| WO2022036176A1 (en) | N-cyclyl-sulfonamides useful for inhibiting raf | |
| MX2010013107A (es) | Compuestos de isoindol 5-sustiuidos. | |
| MXPA01002175A (es) | Derivados de quinazolina como medicamentos. | |
| UA124090C2 (uk) | Інгібітори тирозинкінази | |
| TW201716412A (zh) | 稠合嘧啶化合物或其鹽 | |
| US12440494B2 (en) | Compounds useful for inhibiting RAF dimers | |
| EP2807162B1 (de) | Substituierte phenylimidazopyrazole und ihre verwendung | |
| JP2001302515A (ja) | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 | |
| EP3120852B1 (en) | Preventive and/or therapeutic agent for immune diseases | |
| CN114829370B (zh) | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 | |
| US9434714B2 (en) | Pyrimidine imidazole amines as modulators of kinase activity | |
| CN103509022B (zh) | 黄嘌呤衍生物 | |
| KR20230094166A (ko) | Aak1을 억제하는 바이러스성 질환 또는 뇌 질환의 예방 또는 치료용 약학적 조성물 | |
| AU2011202523B2 (en) | A2B adenosine receptor antagonists | |
| HK1093736B (en) | Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea | |
| HK1219735B (en) | Quinoline derivative |